NASDAQ:DRMA - Dermata Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.33
  • Forecasted Upside: 156.41 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.81
▼ -0.29 (-5.69%)

This chart shows the closing price for DRMA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dermata Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DRMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DRMA

Analyst Price Target is $12.33
▲ +156.41% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Dermata Therapeutics in the last 3 months. The average price target is $12.33, with a high forecast of $14.00 and a low forecast of $9.00. The average price target represents a 156.41% upside from the last price of $4.81.

This chart shows the closing price for DRMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Dermata Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/21/2021Brookline Capital ManagementReiterated RatingBuy$14.00High
9/21/2021Brookline Capital AcquisitionInitiated CoverageBuy$14.00High
9/14/2021Maxim GroupInitiated CoverageBuy$9.00Medium
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/28/2021

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Dermata Therapeutics logo
Dermata Therapeutics Inc. is a privately held biotechnology company. It focused on treatment of medical and aesthetic skin diseases and conditions. The company's product pipeline consist DMT310 which is in clinical trial. Dermata Therapeutics Inc. is based in SAN DIEGO.
Read More

Today's Range

Now: $4.81
Low: $4.81
High: $5.00

50 Day Range

MA: N/A

52 Week Range

Now: $4.81
Low: $4.08
High: $6.50

Volume

3,148 shs

Average Volume

380,883 shs

Market Capitalization

$40.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Dermata Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Dermata Therapeutics in the last twelve months: Brookline Capital Acquisition Corp., Brookline Capital Management, and Maxim Group.
View the latest analyst ratings for DRMA.

What is the current price target for Dermata Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Dermata Therapeutics in the last year. Their average twelve-month price target is $12.33, suggesting a possible upside of 156.4%. Brookline Capital Acquisition Corp. has the highest price target set, predicting DRMA will reach $14.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $9.00 for Dermata Therapeutics in the next year.
View the latest price targets for DRMA.

What is the current consensus analyst rating for Dermata Therapeutics?

Dermata Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DRMA will outperform the market and that investors should add to their positions of Dermata Therapeutics.
View the latest ratings for DRMA.

How do I contact Dermata Therapeutics' investor relations team?

The company's listed phone number is 858-223-0882. The official website for Dermata Therapeutics is www.dermatarx.com.